

Sensitivity of B-Lymphoma cells to adriamycin after 4 hour exposure
% Cytotoxicity
100
80
60
40
20
0
Control
ADM(2x10-7M)
ADM(4x10-8M)

FIGURE 1



Anti-CD40L antibody (IDEC-131) overrides CD40L mediated resistance to killing by ADM of B-lymphoma cells
% Cytotoxicity
100
80
60
40
20
0
-20
-40
Control
ADM(2x10-7M
ADM(4x10-8M)
gp39
gp39+ADM(2x10-7M)
gp39+ADM (4x10-8M)
gp39+ADM(2x10-7M)
gp39+ADM(4x10-8M)
IDEC-131

FIGURE 2.a

Effect of RITUXAN on normal and sCD40L pre-treated DHL-4 cells




FIGURE 2.b.



Blocking of CD40L mediated cell survival of B-CLL by anti-CD40L antibody (IDEC-131)
% Cytotoxicity
100
80
60
40
20
0
IDEC-131/10ug/ml
IDEC-131/3.3ug/ml
IDEC-131/1.1ug/ml
IDEC-131/0.3ug/ml
IDEC-131/10ug/ml
IDEC-131/3.3ug/ml
IDEC-131/1.1ug/ml
IDEC-131/0.3ug/ml
(-) sCD40L
(+) sCD40L

FIGURE 3.a



Blocking of CD40L mediated survival of B-CLL by IDEC's C2B8
% Cytotoxicity
100
80
60
40
20
0
C2B8/10ug/ml
C2B8/3.3ug/ml
C2B8/1.1ug/ml
C2B8/0.3ug/ml
C2B8/10ug/ml
C2B8/3.3ug/ml
C2B8/1.1ug/ml
C2B8/0.3ug/ml
(-) sCD40L
(+) sCD40L

FIGURE 3.b

FIGURE 4

